Edgewise boosts R&D spending with drug trials underway
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending slightly in the third quarter of 2024 from the preceding quarter as key drug trials are underway.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
